UNSPSC 51145200: Stimulant or anorexiant piperidines

This classification a family of hexahydropyridines, called piperidines, that increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT PIPERIDINES.

UNSPSC 51145200 Stimulant or anorexiant piperidines is a Class code that in recent state and local procurement activity does not align with its nominal pharmaceutical scope. The recent opportunities tagged to this code instead reflect purchases of naloxone (an opioid antagonist unrelated to piperidines), generic multi-source pharmaceuticals and OTC products distributed through cooperative purchasing channels, and exploratory vendor outreach for direct-to-manufacturer prescription programs. State and local issuers soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The actual buying pattern suggests the code may be misapplied in state and local systems, or that the taxonomy does not cleanly map the emergency-response and general-pharmacy categories these jurisdictions are procuring.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), requiring quarterly deliveries to the Seminole County Community Health Building in Sanford with fixed-fee pricing and a two-year contract term plus optional one-year renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal award timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The MMCAP procurement requires cGMP and Drug Supply Chain Security Act compliance and mandates distribution through three authorized wholesalers.